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ABSTRACT
Background: Recurrent Clostridioides difficile infection (CDI) is a cause of increased burden on
the healthcare system and factors associated with this disease merit understanding. This study
aimed to determine the incidence rate and to describe the factors associated with recurrent CDI
cases in New Haven County from 2015 to 2020. It also examined the trends in annual recurrent
CDI cases across epidemiological classes.
Methods: This study utilized data from a population-based surveillance program of the
Healthcare-Associated Infectious Community Interface (HAIC) Program within the Connecticut
Emerging Infectious Program (CT EIP) at Yale School of Public Health which served all
residents of New Haven County. Annual incidence rates of CDI and recurrent CDI in aggregate
and by epidemiological class were calculated. Logistic regression analysis was carried out to
determine factors associated with recurrent CDI.
Results: Among 7,023 CDI cases from 2015-2020, the incidence rate of CDI in 2015 and 2020
was 165.2 and 107.8 per 100,000 persons respectively (median=140.2/100,000 persons;
IQR=25.6/100,000 persons). Overall, 12% of 4,301 CDI cases with complete chart reviews had
recurrent CDI, which made up 13.6% of all HCFO-CDI, 14.1% of all CO-HCFA CDI, and
10.5% of all CA-CDI. Specifically, 18.1 and 16.9 per 100 persons in 2015 and 2020 respectively
had recurrent CDI (median=11.3/100 persons; IQR=4.7/100 persons). There were a 37.3% and
2.3% increase in recurrent CDI among HCFO and CA cases respectively from 2019 to 2020. A
significant proportion of those who had recurrent CDI were older (median age=70.0 years,
IQR=23.0 years; median age of non-recurrent group=64.0 years, IQR=26.0 years, p<0.001),
female (recurrent of 66.0% vs non-recurrent of 61.3% p<0.039), White race, non-Hispanic, and
had healthcare-associated incident CDI. In the final multivariable model, there was a higher risk

of recurrent CDI among individuals who had malignancies (OR, 1.51; 95% CI, 1.11-2.07), used
nitrofurantoin (OR, 2.37; 95% CI, 1.23-4.58), or were of White race. Also, cases with incident
CDI in 2017 (OR, 0.43; 95% CI, 0.26-0.73), 2018 (OR, 0.60; 95% CI, 0.37-0.97), and 2019 (OR,
0.50; 95% CI, 0.30-0.84) had lower risk of recurrent CDI when compared with incident CDI
cases in 2015.
Conclusions: There was a lowered risk of recurrent CDI over time (from 2015-2019) which may
reflect effective measures in management of CDI. The loss of this pattern in 2020 with an
increase in HCFO recurrent cases may reflect the impact of the COVID-19 pandemic in 2020.
Older persons, White individuals, and those with malignancies are particularly vulnerable to
recurrent CDI.

Keywords: Chronic Disease Epidemiology, Thesis, Clostridioides difficile, CDI, recurrent CDI,
recurrent Clostridioides difficile
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INTRODUCTION
Background and literature review
Clostridioides difficile infection (CDI) is one of the most common causes of healthcareassociated infection1 with significant morbidity and mortality.2 CDI is classified based on
epidemiology into healthcare facility-onset (HCFO), community-onset healthcare facilityassociated (CO-HCFA), and community-associated (CA).1 Both HCFO and CO-HCFA are
healthcare-associated CDI, differing in where an individual is located at symptom onset. Despite
evidence of decreasing healthcare-associated CDI cases in the United States, there appears to be
an increase in community-acquired CDI.3
Recurrent CDI, defined as an episode of symptom onset and positive assay result
following an episode with positive assay result in the previous 2-8 weeks4, is associated with
increased burden on the healthcare system and increased medical costs.2 It is estimated that as
high as 35% of CDI cases will experience a first recurrence, with increasing risk of recurrence
following the previous episode.2 Specific to recurrent CDI, studies have demonstrated that those
of older age or female sex have an increased risk of recurrence when compared to their
respective counterparts.2 CDI episodes have been shown to have worse outcomes with each
subsequent recurring episode.2,5 Prior studies have described the possible factors that may
increase the risk of recurrence as microbiological factors6–9, clinical characteristics5,10–13, or
epidemiological factors.13 Studies also describe social factors like living environment that may
be linked to recurrent CDI, although these were limited to older populations.14,15 Increasing cases
of community-acquired CDI3 may translate to an increase in recurrent CDI in the community
despite evidence of reduction in overall number of CDI cases.

Specific Aims and Hypothesis
The study aims to describe the socio-demographic characteristics, clinical comorbidities
and medical history, and medication history of the population presenting with recurrent
Clostridioides difficile infection (CDI) in New Haven County from 2015-2020 using populationbased surveillance data from the Connecticut Emerging Infectious Program (CT EIP). The study
also aims to examine trends in recurrent CDI stratified by epidemiological class (HCFO, COHCFA, or CA) and to identify possible factors that are associated with recurrent CDI in the study
population. Understanding the trends in recurrent CDI as well as the factors associated with it
will provide insight into the effectiveness of current preventive measures of recurrent CDI,
especially given its burden on the healthcare system. Observations from previous studies of
increasing cases of recurrent CDI among CA incident cases while recurrent CDI decreases
among healthcare-associated incident CDI may require a pivot in the measures for managing
CDI among those with CA-CDI. However, with the COVID-19 pandemic and the consequent
increase in hospital admissions16, there is an expected increase in recurrent CDI among those
with healthcare-associated CDI but to what extent and what factors may be associated with that
need further exploration.
The hypothesis of this study is that there will be decreasing incidence of recurrent CDI
over time, prior to the pandemic, with a higher proportion of these cases developing as
community-associated recurrent CDI given the measures in place to monitor and prevent
recurrence of CDI in healthcare facilities. Older individuals and individuals with comorbidities
are also expected to have a higher risk of recurrence.

METHODS
Study Population and Design
This study included surveillance data from January 2015 through December 2020 from the
Healthcare-Associated Infections Community Interface (HAIC) Program of the Connecticut
Emerging Infectious Program (CT EIP) at Yale School of Public Health, serving New Haven
County. The HAIC program and its CDI surveillance program are described elsewhere.1 In brief,
the CDI surveillance program at CT EIP monitors the population-based incidence and burden of
CDI within New Haven County through active surveillance of New Haven County residents
irrespective of location of CDI diagnosis. CDI was defined as a positive diagnostic stool
specimen using either or both of toxin assay and molecular assay of any resident of New Haven
County greater than one year of age. Recurrent CDI was defined as a CDI case with at least one
positive stool specimen occurring between two and eight weeks of an incident CDI episode. CDI
cases occurring after eight weeks of incident CDI were classified as new incident cases while
those occurring within two weeks of incident CDI were classified as duplicate cases.1
Sample Size and Data Collection
The sample included reported CDI cases from January 2015 to December 2020 and this
was used to calculate the incidence rates of CDI and recurrent CDI. Further analysis of the
sample occurred after exclusion of CDI cases with chart reviews not indicated as complete
(n=430). Further exclusions included if the participant was HCFO but was not selected for
complete chart review (n=2238), and/or if they had no epidemiological class assigned to them
(n=74) (Figure 1). All community-associated CDI cases and a 1 in 10 random selection of
healthcare-associated cases underwent complete chart reviews at EIP sites.1 Participants with no

epidemiological class assigned usually occurred due to medical charts being unavailable for
abstraction after several attempts at retrieval. All remaining cases from the surveillance data
were included and thus power for the study was not calculated.
A comparison between variables selected for index study and those not selected (Table
S1a) shows that a significantly lower proportion of those selected for analysis had HCFO
classification, were younger individuals, and had a lower mortality. Due to the significantly
lower proportion of HCFO cases among selected cases, a comparison of HCFO cases included
and excluded in the final analysis was then carried out which showed no significant difference in
sex, ethnicity, and mortality rate between selected and excluded HCFO cases. However, there
were significantly higher proportions of White individuals, younger individuals, and those who
had incident CDI in 2020 among included HCFO cases (Table S1b).
Figure 1. Case Selection for Inclusion in Data Analysis

N=7301

Cases with charts not marked as
complete are excluded (n=430)

Cases not selected for complete
chart reviews are excluded (n=2238)

Cases with no assigned
epidemiological class are excluded
(n=74)

Selected Sample Size, N= 4301

Participant Characteristics and Epidemiological Class
Data were obtained from medical record abstraction carried out by epidemiologists and
research scientists of HAIC at CT EIP. The retrieved information was classified for this study
into categories of sociodemographic factors, medication history, medical history, clinical
interventions, and treatment received/outcome.
For this study, sociodemographic variables included age, sex, race (grouped as White,
Black, Asian/American Indian/Pacific Islanders, and Mixed race/Unknown race. Mixed race
within available data is a combination of either Black and White race (n=5) or Black and
American Indian race (n=1)). Ethnicity was grouped into Non-Hispanic or Hispanic categories.
Medication taken within the twelve weeks prior to positive incident CDI sample collection was
collected as medication history. This included a history of use of proton pump inhibitors (PPI),
histamine receptor-2 (H2 receptor) blockers, antibiotics, and immunotherapeutic agents.
Immunotherapeutic agents included steroids, chemotherapy agents, and other
immunosuppressants while antibiotics were classified into the different classes of antibiotics:
penicillin, macrolides, aminoglycosides, cephalosporins, fluoroquinolones,
trimethoprim/trimethoprim-sulfamethoxazole (TMP/TMP-SMZ), carbapenem, glycopeptide,
tetracycline, nitroimidazole, and nitrofurans (Table S2). Medical history included a history of
CDI, myocardial infarction (MI), peripheral vascular disease (PVD), chronic obstructive
pulmonary disease (COPD), chronic liver disease (CLD) with or without complications,
immunocompromised states (including HIV with or without AIDS, diabetes mellitus (DM) with
or without complications, primary immunodeficiency, solid organ and/or hematopoietic stem cell
transplant), cerebrovascular accidents (CVA, including stroke, and transient ischemic attacks),

chronic cognitive deficits and/or dementia, heart failure, connective tissue diseases,
gastrointestinal diseases (including peptic ulcer disease, diverticular disease, inflammatory bowel
diseases, and short gut syndrome), malignancies (including hematological, and solid organ
malignancy with or without metastasis), and morbid obesity (defined as body mass index ≥
40kg/m2). Clinical data relevant to determining epidemiological class (clinical exposures)
included admission within six days of sample collection, CDI as reason for admission,
participants who had an emergency room visit, or underwent dialysis, or surgery within twelve
weeks before sample collection. Treatment received was recorded as antibiotics (including
vancomycin, metronidazole, fidaxomicin, rifaximin, and nitazoxanide), stool transplant, and/or
probiotics as a single course. Participants who received more than one course of treatment were
defined as completing a course of antibiotic as specified above with the administration of another
course without regard to route of administration.
The process of assigning epidemiological class has been described elsewhere.1 Briefly, a
case was classified as either healthcare facility onset (HCFO), or community-onset cases. HCFO
was assigned if it was a hospital-onset CDI with a positive stool collected > 3days after hospital
admission or long-term care facility (LTCF) onset with positive stool collected in a LTCF (or
long-term acute care hospital - LTACH) or from a LTCF resident admitted to a hospital.
Community-onset was defined by a positive stool collected as an outpatient or within 3 days of
hospital admission. Community-onset CDI was further classified into community-associated
(CA) if there was no mention of healthcare facility admission in the prior twelve weeks; all other
community-onset cases were considered community-onset healthcare-facility associated (COHCFA).1,3 Both CO-HCFA and HCFO cases are considered healthcare-associated CDI.

Primary Outcome
The primary outcome was recurrence of CDI defined as a positive CDI sample using
either or both of toxin assay or molecular assay and occurring at least more than two weeks but
within eight weeks following an episode of incident CDI. All information on the primary
outcome was collected through medical chart abstraction. Information on mortality within 90
days of specimen collection was also collected through this means and validated using the
Connecticut death registry database.
Data Analysis
The annual incidence rates of CDI, including recurrent cases, per 100,000 persons for the
study period was calculated using the New Haven County population for each period as a
denominator (Figure 2).
Figure 2. New Haven County Population from 2015-2020
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Source: Data Census17, Data Commons18, CT Department of Public Health19

The annual incidence rates of CDI by epidemiological class per 100,000 persons were also
calculated for each study period using the New Haven County Population as denominator. The
incidence rate for recurrent CDI cases per 100 initial cases was calculated by using CDI cases
selected for analysis as denominators for each study year. In calculating the incidence rate of
recurrent CDI, cases with mortality within two weeks of incident CDI were excluded from the
denominator. This data was available through chart reviews and validated using the Connecticut
death registry. Similarly, the incidence rates of recurrent CDI cases per 100 initial cases by
epidemiological class were calculated. Sociodemographic characteristics, medical history,
medication history, clinical exposures, and treatment received by participants were described
according to whether they developed recurrent CDI. These variables were also described by
epidemiological class (HCFO, CO-HCFA, or CA) for all participants with recurrent CDI. The
Shapiro-Wilk test was used to test for the normality of continuous variables (i.e., age). Given its
non-normal distribution, the Kruskal-Wallis test was then used to describe the differences
between groups for age, and the chi-square (Fishers exact test if cell frequency was ≤ 5) was
used for categorical variables.
Univariate and multivariable analyses were performed using logistic regression models.
Univariate models were used to assess the relationship between year of incident CDI,
race/ethnicity, age, sex, medication history, comorbidities, clinical exposures, treatment received,
and epidemiological class and the likelihood of recurrent CDI. Spearman’s correlation was used
to measure for correlated variables; diabetes mellitus and the composite variable representing
immunocompromised had a correlation coefficient of 0.81 while dialysis and the composite
variable representing immunocompromised had a weak correlation (r =0.31). Penicillins,
cephalosporins, and glycopeptides were individually weakly correlated to the composite

antibiotic variable (r= 0.38, 0.44, and 0.40 respectively) while glycopeptide was correlated to
cephalosporins (r=0.37) and fluoroquinolones to nitroimidazoles (r=0.33). Among other
variables, the correlation coefficients were <0.30. The missingness was assumed to be at random
with most variables having missing values <5% in the total sample and for individual
epidemiological class (Table S3).
To determine factors that were independently associated with recurrence, multivariable
logistic regression that involved the addition of pre-specified domains in a sequential manner
was employed. Selection of covariates for the multivariable regression was based on statistical
significance at p=0.05 level in the univariate model, variable correlation with each other (weak
correlation held at r<0.30), clinical judgement, and results from literature search.20,21
Multivariable model building using the forward elimination allowed for visualization of the
effect of each category on the overall model.22 The multivariable models were then built as
follows; Model 1 included year of incident CDI, age, sex, race, and ethnicity. Model 2 included
year of incident CDI, age, sex, race, ethnicity, use of PPI, H2 receptor blockers, antibiotics,
penicillin, cephalosporin, tetracycline, nitroimidazole, nitrofuran, and immunotherapy. It also
included previous CDI episode, immunocompromised state, CVA, malignancies, chronic
cognitive deficit/dementia, admitted due to CDI, emergency room visit, dialysis, and surgery
done. Model 3 included the epidemiological classes in addition to variables in model 2. Results
from the regression models are presented as odds ratio (OR) of recurrent CDI for each covariate
and its 95% confidence interval (95% CI). Using the Wald’s chi-square to test for statistical
significance in relevant multivariable models, a series of two-way interactions was tested
between race and age; race and sex; and between race and any comorbidities, medication history,
clinical exposures that were statistically significant in the univariate regression. All statistical

analysis was done using SAS version 9.4 (SAS Institute) with two-tailed tests of significance at
α=0.05 level.

RESULTS
Incidence Rates of CDI and Recurrent CDI
From 2015 to 2020, there was a total of 7,023 incident CDI cases of which 4,301 cases
had a complete chart review. The incidence rate of CDI was notably different between the study
years ranging from 165.2/100,000 persons in 2015 to 107.8/100,000 persons in 2020
(median=140.2/100,000 persons; IQR=25.6/100,000 persons). The incidence of recurrent CDI
was different across the study period with 18.1/100 incident cases in 2015, 12.1/100 incident
cases in 2019, and 16.9/100 incident cases in 2020 (median=11.3/100 incident cases;
IQR=4.7/100 incident cases) (Figure 3).
When stratified according to epidemiological class, the incidence of total CDI cases
showed a fluctuating pattern and an overall decrease of healthcare facility onset (HCFO) CDI
(76.4 and 38.4/100,000 cases in 2015 and 2020 respectively) and community-associated (CA)
CDI (63.0 and 34.5/100,000 cases in 2015 and 2020 respectively) over time. The incidence rates
for recurrent CDI in community-onset healthcare facility associated (CO-HCFA) CDI appeared
to generally follow a pattern of reduction across the years while there was an observed increase
in recurrent CDI especially for HCFO in 2020 (11.6, 10.0, and 19.7/100 incident cases in 2018,
2019, and 2020 respectively). The increases in recurrent CA were observed to occur gradually
beginning from 2018 (Figure 4). However, throughout the study period, the rate of recurrent
CA-CDI cases generally remained consistently below the rate of recurrent CDI among HCFO
cases. Within HCFO epidemiological class, there was a 37.3% increase in recurrent CDI from
2019 to 2020. This contrasts a 6.0% decrease between 2018 and 2019. There was a similar
pattern of recurrent CDI in the CA class with a 2.3% increase between 2019 and 2020 from a
0.8% decrease in the 2018 to 2019 period. Overall, 12% of 4,301 CDI cases with complete chart

reviews had recurrent CDI, which made up 13.6% of all HCFO-CDI, 14.1% of all CO-HCFA
CDI, and 10.5% of all CA-CDI.
Sociodemographic and Clinical Characteristics of Recurrent CDI
Among the 4,301 CDI cases with complete chart reviews, the median age was 65.0 years
(IQR of 26.0 years) with 61.9% female, 73.7% White individuals, 8.4% Hispanic individuals,
and 12% of cases presenting with recurrent CDI. A significantly higher proportion of those who
had recurrent CDI were older individuals (median age= 70.0 years, IQR=23.0 years; median age
for non-recurrent cases=64.0 years, IQR = 26.0 years), female (recurrent = 66.0 % vs nonrecurrent =61.3%, p<0.039), White, non-Hispanic, and those who had incident CDI cases
classified as healthcare-associated incident CDI (HCFO and CO-HCFA) (Table 1). A higher
proportion of HCFO (13.6%) and CO-HCFA (14.1%) cases had recurrent CDI while only 10.5%
of CA cases were noted as having a recurrence. There was no significant difference in the
proportions of those who had recurrent CDI when a history of CDI, immunocompromise, COPD,
CVA, or cognitive impairment/dementia were assessed. There was also no significant difference
in use of PPI, H2 receptor blocker, or immunotherapy when those with recurrent CDI were
compared to those without recurrent CDI. However, significant differences were noted for
antibiotic use specifically cephalosporins, tetracyclines, and nitrofurans with higher proportions
noted among those with recurrent CDI (Table 1).
When comparing recurrent CDI by epidemiological class, a significantly higher
proportion of recurrent CDI cases in HCFO were older (median age =74.0 years; IQR=20.0
years), White, and non-Hispanic individuals (Table 2). This group also had a significantly higher
proportion of individuals with COPD, CVA, heart failure, MI, PVD, peptic ulcer disease, morbid
obesity and immunocompromised states including DM. Although the proportion of individuals

with previous CDI was higher in the HCFO group, this did not reach statistical significance
(p=0.44). Proportions of individuals with malignancies, a history of nitrofurantoin use, admitted
due to incident CDI, and emergency room use were significantly higher among CO-HCFA CDI
class. When assessing treatment of incident CDI among those with recurrent CDI, there was a
significantly higher proportion of vancomycin use among HCFO CDI with this group also
having a higher proportion of more than one course of incident CDI treatment although this was
not statistically significant (Table 2). Probiotic use as treatment for incident CDI was not
significantly different across the three epidemiological classes (p=0.24).
Factors Associated with Recurrent CDI
Univariate analysis showed that females (OR, 1.23; 95% CI, 1.01-1.49), and older
persons (OR, 1.01; 95% CI, 1.01-1.02) were more likely to have recurrent CDI when compared
with their counterparts. Clinical factors significantly associated with higher odds of recurrent
CDI were malignancy, emergency room use, and prior use of antibiotics in aggregate and
specifically for the use of cephalosporins, tetracycline, and nitrofurantoin (Table S4). There was
also a significantly higher risk of recurrent CDI in White individuals compared to Black
individuals (OR for Black individuals, 0.56, 95% CI 0.39-0.81) and in HCFO incident cases
compared to CA cases (OR for CA cases, 0.75; 95% CI, 0.57-0.97) (Table S4).
The results of the multivariable models for recurrent CDI are presented in Table 3. Black
race, and year of incident CDI (except 2020) was associated with lower odds of recurrent CDI
when compared with White race and 2015 respectively. This association was attenuated in the
final model for incident CDI occurring in 2016 (vs 2015) but remained significant for 2017 (OR,
0.43; 95% CI, 0.26-0.73), 2018 (OR, 0.60; 95% CI, 0.37-0.97), and 2019 (OR, 0.50; 95% CI,
0.30-0.84) (all compared with 2015), and for Black race compared with White race (OR, 0.50;

95% CI, 0.30-0.83). When year of incident CDI was regressed as an ordinal variable (2015 to
2020 represented by numbers 1 to 6 and regressed as is), there was no statistical significance in
the univariate analysis and multivariable results for all four models. In the final model,
participants with malignancies were 51% more likely to develop recurrent CDI (OR, 1.51; 95%
CI, 1.11-2.07) while nitrofurantoin use had 137% higher odds for recurrent CDI (OR, 2.37; 95%
CI, 1.23-4.58).
Interaction between race and variables significant in the univariate analysis were tested
since race was the only socio-demographic variable that remained significant in the final
multivariable model. Sex, age, and all medical history, medication history, and clinical
interventions with a significant univariate analysis were tested for interaction with race in
multivariable models that contained the index variable. Only emergency room use significantly
modified the effect of Mixed race/unknown race on recurrent CDI (P interaction = 0.044 and 0.041
in models 2 and 3 respectively). Specifically, participants of Mixed/Unknown race who visited
the emergency room within twelve weeks prior to sample collection were more likely to have
recurrent CDI while Mixed/Unknown race participants who did not use the emergency room
within similar timeframe were less likely to have recurrent CDI.

DISCUSSION
We observed an increase in incidence rates of recurrent CDI from 2019 to 2020 despite
initial decreases from 2015 to 2018. When further stratification was carried out, we observe that
this increase in recurrent CDI was largely due to an increase in recurrent healthcare facility onset
(HCFO) CDI in 2020, since the increases in recurrence rates for community-associated (CA)
cases have occurred gradually from 2018-2020. These observed increases in recurrent CDI were
despite a general reduction in overall CDI cases from 2015-2020. After adjusting for year of
incident CDI, sex, age, race, ethnicity, medication history, comorbidities, clinical exposures, and
epidemiological class of incident CDI, we observed significantly increased risk of recurrent CDI
among cases who were admitted for CDI care and those with a history of malignancy, and
nitrofurantoin use. While there was no significant association between recurrent CDI and 2020 as
year of incident CDI, it is observed that the lower risk of recurrent CDI in all multivariable
models for this group were not statistically significant when compared to 2015 as year of
incident CDI.
This study highlights several important findings. The observed decrease in incidence of
recurrent CDI from 2015 to 2018 extends known literature by emphasizing an overall lower rate
of recurrent CDI12 and also in all epidemiological classes of recurrent CDI3 while also reflecting
a continued decrease in recurrent CDI from prior to 2015.23 This can be extrapolated to mean
that current measures for managing and preventing recurrent CDI, including restrictions on
prescription of fluroquinolones3,24, infection control measures25, and possibly treatment
concordance with approved guidelines,26 are effective enough to produce a notable reduction in
these cases. Studies of recurrent CDI rates in 2020 are scarce, thus this study provides one of the
first evidences of increasing rates of recurrent CDI from 2019 to 2020. Although there were

modifications in the case report form (CRF) for CDI reporting in 2019 (Appendix IV) and
improvements in the laboratory techniques for detection of CDI, these would not explain the
noticed increases in recurrent CDI occurring from 2019 to 2020 without a similar pattern
occurring from 2018 to 2019. Given that the major distinguishing factor between the year 2019
and 2020 is the COVID-19 pandemic, the increase in 2020 could be linked to it.
Prior studies have suggested that persons with a history of malignancy27, prior antibiotic
use24,28, increasing age26,29, female sex29, and White race29 have an increased risk of CDI
recurrence. While this study shows that these factors are important predictors of recurrent CDI,
adjusting for patient-level risk factors nullified their significance in predicting recurrent CDI.
Significant predictors of recurrent CDI in the final model were year of incident CDI, White race,
a history of malignancy, admission for incident CDI care, and nitrofurantoin use. It is worth
noting that nitrofurantoin is prescribed for conditions like urinary tract infection, the commonest
cause of bacteremia among older populations.30,31 We can therefore draw parallels between the
significant risk factors of recurrent CDI from this study and some known factors that lead to
severe COVID-19 disease: older age32,33, and a history of malignancy.34 Taken together, these
could at least in part explain the increase in recurrent CDI in 2020, in addition to antibiotic
prescription in treatment of COVID-19.35,36 Further understanding of the effect of COVID-19 on
the incidence of recurrent CDI and other factors that may have influenced increased rates of
recurrent CDI during the pandemic can be utilized in focused interventions on recurrent CDI
prevention during this pandemic era.
Although nitrofurantoin is known to have minimal effect on bowel flora given that it
concentrates in the urinary tract with low serum concentration37, this study shows a significant
relationship between nitrofurantoin use and increased risk for recurrent CDI. This could be due

to the higher rates of prescription of multiple antibiotics to older populations.38,39 Other studies
have found that there is a tendency for inappropriate antibiotic use in long-term care facilities.40–
42

However, after controlling for overall antibiotic use, nitrofurantoin use remained significant.

Further studies into possible explanatory factors are needed as currently available clinical factors
do not completely explain increased recurrent CDI.43
Recommendations
The findings from this study show significant associations between recurrent CDI and
patient-level factors including race, and clinical factors such as a history of malignancy and
nitrofurantoin use. These associations exist in this study in addition to the increase in recurrent
CDI in 2020 despite a decline in recurrent cases from 2015 to 2019. These peculiarities therefore
require further study into the effect of COVID-19 on the risk of recurrent CDI especially among
older patients and those with malignancies.
The high risk of further recurrences following an initial recurrence2 makes recurrent CDI
a worrisome disease that requires further research in predicting a risk model for its prevention in
persons presenting with an initial incident CDI. With a trend tending towards an increase of
recurrent CDI among CA-CDI, it is particularly important to characterize environmental and
possible social determinants of health that may be associated with CDI recurrence.
Understanding these factors would be helpful in formulating targeted preventive programs within
communities.
Limitations
This study has several limitations. First, the protocol for chart reviews used by HAIC
allows for a limited random sampling of 1 in 10 HCFO cases. This could provide a potential

point of bias given that information on CDI recurrence is unavailable for unsampled HCFO
cases. Second, the review and modification of the CDI case report forms (CRF) over the years
has helped improve reporting of patient-level characteristics of CDI cases. However, this has
also produced variations in the CRF, and the way information is collected. This is particularly
noticeable in the CRF change in 2019 (Appendix IV) with inclusion of information such as
route of medication for treatment of previous CDI, and number of courses of treatment received,
which could possibly be important predictors of recurrence. Lastly, although annual
advancements and reviews in CDI testing, detection, and reporting have produced more complete
surveillance data, this could produce artifactual increases in CDI and recurrent CDI incidence
rates which this study does not account for. Thus, there is likely to be larger magnitude
differences in incidence rates from year to year than those presented here.

CONCLUSIONS
Over the study period, there was a notable decline in the incidence of CDI and recurrent
CDI until 2020 when there was a sharp increase. The initial reduction in incidence of recurrent
CDI over time may reflect the effectiveness of measures for management and/or prevention of
CDI which has led to decreased rates of recurrent CDI. The increased risk of CDI recurrence in
those with a history of nitrofurantoin use, commonly prescribed for urinary tract infections in
older persons, and those with malignancies reflects a particularly vulnerable population that
requires targeted programs to prevent recurrent CDI.

APPENDIX I - References
1.

Clostridioides difficile Infection (CDI) Tracking | HAIC Activities | HAI | CDC. Published
June 22, 2021. Accessed July 30, 2021. https://www.cdc.gov/hai/eip/cdiff-tracking.html

2.

Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent
Clostridioides difficile infection. Therap Adv Gastroenterol. 2021;14:17562848211016248.
doi:10.1177/17562848211016248

3.

Guh AY, Mu Y, Winston LG, et al. Trends in U.S. Burden of Clostridioides difficile
Infection and Outcomes. New England Journal of Medicine. 2020;382(14):1320-1330.
doi:10.1056/NEJMoa1910215

4.

McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium
difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society
of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical
Infectious Diseases. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085

5.

Thomas E, Bémer P, Eckert C, et al. Clostridium difficile infections: analysis of recurrence
in an area with low prevalence of 027 strain. J Hosp Infect. 2016;93(1):109-112.
doi:10.1016/j.jhin.2016.01.015

6.

Khanna S, Montassier E, Schmidt B, et al. Gut microbiome predictors of treatment response
and recurrence in primary Clostridium difficile infection. Alimentary Pharmacology &
Therapeutics. 2016;44(7):715-727. doi:10.1111/apt.13750

7.

Richardson C, Kim P, Lee C, Bersenas A, Weese JS. Comparison of Clostridium difficile
isolates from individuals with recurrent and single episode of infection. Anaerobe.
2015;33:105-108. doi:10.1016/j.anaerobe.2015.03.003

8.

Seekatz AM, Wolfrum E, DeWald CM, et al. Presence of multiple Clostridium difficile
strains at primary infection is associated with development of recurrent disease. Anaerobe.
2018;53:74-81. doi:10.1016/j.anaerobe.2018.05.017

9.

Martin JSH, Eyre DW, Fawley WN, et al. Patient and Strain Characteristics Associated
With Clostridium difficile Transmission and Adverse Outcomes. Clin Infect Dis.
2018;67(9):1379-1387. doi:10.1093/cid/ciy302

10. Kim J, Seo MR, Kang JO, Kim Y, Hong SP, Pai H. Clinical characteristics of relapses and
re-infections in Clostridium difficile infection. Clin Microbiol Infect. 2014;20(11):11981204. doi:10.1111/1469-0691.12704
11. Ma GK, Brensinger CM, Wu Q, Lewis JD. Increasing Incidence of Multiply Recurrent
Clostridium difficile Infection in the United States: A Cohort Study. Ann Intern Med.
2017;167(3):152-158. doi:10.7326/M16-2733

12. Abdelfatah M, Nayfe R, Nijim A, et al. Factors Predicting Recurrence of Clostridium
difficile Infection (CDI) in Hospitalized Patients: Retrospective Study of More Than 2000
Patients. J Investig Med. 2015;63(5):747-751. doi:10.1097/JIM.0000000000000188
13. Gómez S, Chaves F, Orellana MA. Clinical, epidemiological and microbiological
characteristics of relapse and re-infection in Clostridium difficile infection. Anaerobe.
2017;48:147-151. doi:10.1016/j.anaerobe.2017.08.012
14. Haran JP, Bradley E, Howe E, Wu X, Tjia J. Medication Exposure and Risk of Recurrent
Clostridium difficile Infection in Community-Dwelling Older People and Nursing Home
Residents. Journal of the American Geriatrics Society. 2018;66(2):333-338.
doi:10.1111/jgs.15176
15. Scaria E, Powell WR, Birstler J, et al. Neighborhood disadvantage and 30-day readmission
risk following Clostridioides difficile infection hospitalization. BMC Infect Dis.
2020;20(1):762. doi:10.1186/s12879-020-05481-x
16. Jeffery MM, D’Onofrio G, Paek H, et al. Trends in Emergency Department Visits and
Hospital Admissions in Health Care Systems in 5 States in the First Months of the COVID19 Pandemic in the US. JAMA Internal Medicine. 2020;180(10):1328-1333.
doi:10.1001/jamainternmed.2020.3288
17. Census - Geography Profile. Accessed March 18, 2022.
https://data.census.gov/cedsci/profile?g=0500000US09009
18. New Haven County Demographics - Place Explorer - Data Commons. Accessed March 18,
2022. https://datacommons.org/place/geoId/09009?category=Demographics
19. Backus K. Town-Level Population Estimates for Connecticut, 2019. Connecticut
Department of Public Health. Published online 2020:3.
20. Lin CC, Li CI, Hsiao CY, et al. Time trend analysis of the prevalence and incidence of
diagnosed type 2 diabetes among adults in Taiwan from 2000 to 2007: a population-based
study. BMC Public Health. 2013;13(1):318. doi:10.1186/1471-2458-13-318
21. Davies K, Lawrence J, Berry C, et al. Risk Factors for Primary Clostridium difficile
Infection; Results From the Observational Study of Risk Factors for Clostridium difficile
Infection in Hospitalized Patients With Infective Diarrhea (ORCHID). Front Public Health.
2020;8:293. doi:10.3389/fpubh.2020.00293
22. Shipe ME, Deppen SA, Farjah F, Grogan EL. Developing prediction models for clinical use
using logistic regression: an overview. J Thorac Dis. 2019;11(Suppl 4):S574-S584.
doi:10.21037/jtd.2019.01.25
23. Guh AY, Mu Y, Baggs J, et al. Trends in incidence of long-term-care facility onset
Clostridium difficile infections in 10 US geographic locations during 2011-2015. American
Journal of Infection Control. 2018;46(7):840-842. doi:10.1016/j.ajic.2017.11.026

24. Kazakova SV, Baggs J, McDonald LC, et al. Association Between Antibiotic Use and
Hospital-onset Clostridioides difficile Infection in US Acute Care Hospitals, 2006–2012:
An Ecologic Analysis. Clinical Infectious Diseases. 2020;70(1):11-18.
doi:10.1093/cid/ciz169
25. Rizzo KR, Yi SH, Garcia EP, Zahn M, Epson E. Reduction in Clostridium difficile
infection rates following a multifacility prevention initiative in Orange County, California:
A controlled interrupted time series evaluation. Infection Control & Hospital Epidemiology.
2019;40(8):872-879. doi:10.1017/ice.2019.135
26. Luc CM, Olson D, Banach DB, Clogher P, Hadler J. Evaluation of Connecticut medical
providers’ concordance with 2017 IDSA/SHEA Clostridioides difficile treatment guidelines
in New Haven County, 2018–2019. Infection Control & Hospital Epidemiology.
2021;42(5):549-556. doi:10.1017/ice.2020.1237
27. Scappaticci GB, Perissinotti AJ, Nagel JL, Bixby DL, Marini BL. Risk factors and impact
of Clostridium difficile recurrence on haematology patients. Journal of Antimicrobial
Chemotherapy. 2017;72(5):1488-1495. doi:10.1093/jac/dkx005
28. Kazakova SV, Baggs J, Yi SH, et al. Associations of facility-level antibiotic use and
hospital-onset Clostridioides difficile infection in US acute-care hospitals, 2012–2018.
Infection Control & Hospital Epidemiology. Published online May 7, 2021:1-3.
doi:10.1017/ice.2021.151
29. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the
United States. N Engl J Med. 2015;372(9):825-834. doi:10.1056/NEJMoa1408913
30. Mouton CP, Bazaldua OV, Pierce B, Espino DV. Common Infections in Older Adults.
AFP. 2001;63(2):257.
31. Cristina ML, Spagnolo AM, Giribone L, Demartini A, Sartini M. Epidemiology and
Prevention of Healthcare-Associated Infections in Geriatric Patients: A Narrative Review.
International Journal of Environmental Research and Public Health. 2021;18(10):5333.
doi:10.3390/ijerph18105333
32. Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection,
severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open.
2021;11(1):e044640. doi:10.1136/bmjopen-2020-044640
33. Cummins L, Ebyarimpa I, Cheetham N, Tzortziou Brown V, Brennan K, PanovskaGriffiths J. Factors associated with COVID-19 related hospitalisation, critical care
admission and mortality using linked primary and secondary care data. Influenza and Other
Respiratory Viruses. 2021;15(5):577-588. doi:10.1111/irv.12864
34. Lee KA, Ma W, Sikavi DR, et al. Cancer and Risk of COVID‐19 Through a General
Community Survey. The Oncologist. 2021;26(1):e182-e185.
doi:10.1634/theoncologist.2020-0572

35. Gouin KA, Creasy S, Beckerson M, et al. Trends in Prescribing of Antibiotics and Drugs
Investigated for Coronavirus Disease 2019 (COVID-19) Treatment in US Nursing Home
Residents During the COVID-19 Pandemic. Clinical Infectious Diseases. 2022;74(1):7482. doi:10.1093/cid/ciab225
36. Knight GM, Glover RE, McQuaid CF, et al. Antimicrobial resistance and COVID-19:
Intersections and implications. Cooper VS, Perry GH, eds. eLife. 2021;10:e64139.
doi:10.7554/eLife.64139
37. Squadrito FJ, Portal D del. Nitrofurantoin. StatPearls Publishing; 2021. Accessed April 16,
2022. https://www.ncbi.nlm.nih.gov/books/NBK470526/
38. Arizpe A, Reveles KR, Aitken SL. Regional variation in antibiotic prescribing among
medicare part D enrollees, 2013. BMC Infectious Diseases. 2016;16(1):744.
doi:10.1186/s12879-016-2091-0
39. Portero de la Cruz S, Cebrino J. Prevalence and Determinants of Antibiotic Consumption in
the Elderly during 2006–2017. International Journal of Environmental Research and
Public Health. 2020;17(9):3243. doi:10.3390/ijerph17093243
40. Raban MZ, Gasparini C, Li L, Baysari MT, Westbrook JI. Effectiveness of interventions
targeting antibiotic use in long-term aged care facilities: a systematic review and metaanalysis. BMJ Open. 2020;10(1):e028494. doi:10.1136/bmjopen-2018-028494
41. Raban MZ, Gates PJ, Gasparini C, Westbrook JI. Temporal and regional trends of antibiotic
use in long-term aged care facilities across 39 countries, 1985-2019: Systematic review and
meta-analysis. PLOS ONE. 2021;16(8):e0256501. doi:10.1371/journal.pone.0256501
42. Crayton E, Richardson M, Fuller C, et al. Interventions to improve appropriate antibiotic
prescribing in long-term care facilities: a systematic review. BMC Geriatrics.
2020;20(1):237. doi:10.1186/s12877-020-01564-1
43. van Rossen TM, van Dijk LJ, Heymans MW, Dekkers OM, Vandenbroucke-Grauls CMJE,
van Beurden YH. External validation of two prediction tools for patients at risk for
recurrent Clostridioides difficile infection. Therap Adv Gastroenterol.
2021;14:1756284820977385. doi:10.1177/1756284820977385

APPENDIX II – Tables and Figures
Figure 3. Annual Incidence Rates of CDI* and Recurrent CDI** in New Haven County
from 2015-2020

Incidence Rates of CDI per 100,000 Persons
200
160
120
80
40
0
2015

2016

2017

2018

2019

2020

*CDI cases were all reported CDI cases in New Haven County

Incidence Rates of Recurrent CDI cases per 100
Initial Cases
20
15
10
5
0
2015

2016

2017

2018

2019

2020

**Recurrent CDI cases were available only for cases with complete chart reviews.

Figure 4. Annual Incidence Rates of CDI and Recurrent CDI* in New Haven County by
Epidemiological Class** from 2015-2020
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*Recurrent CDI cases were available only for cases with complete chart reviews.
**Epidemiological class of the incident cases. These were not available for 74 cases due to
unavailable medical records.

Table 1. Socio-demographic and Clinical Characteristics of Persons with CDI Stratified by
Recurrence of CDI
Variable

Total (N, %)

Recurrent CDI

No Recurrent CDI

(N =515)

(N =3786)

p-value

Sociodemographic Characteristics (%)
Year

0.002

2015

751 (17.5)

115 (22.3)

636 (16.8)

2016

744 (17.3)

86 (16.7)

658 (17.4)

2017

685 (15.9)

68 (13.2)

617 (16.3)

2018

789 (18.3)

77 (15.0)

712 (18.8)

2019

632 (14.7)

68 (13.2)

564 (14.9)

2020

700 (16.3)

101 (19.6)

599 (15.8)

65.0 (26.0)

70.0 (23.0)

64.0 (26.0)

Age (Median, IQR)
Sex

0.039

Male

1640 (38.1)

175 (34.0)

1465 (38.7)

Female

2661 (61.9)

340 (66.0)

2321 (61.3)

Race

<0.001

White

3169 (73.7)

419 (81.4)

2750 (72.6)

Black

430 (10.0)

34 (6.6)

396 (10.5)

38 (0.9)

1 (0.2)

37 (1.0)

664 (15.4)

61 (11.8)

603 (15.9)

Asian/American
Indian/Pacific Islander
Mixed Race/Unknown

<0.001

Ethnicity
Hispanic
Non-Hispanic

0.101
327 (8.4)

31 (6.5)

296 (8.7)

3556 (91.6)

448 (93.5)

3108 (91.3)

Epidemiological Class
HCFO

0.003
610 (14.2)

83 (16.1)

527 (13.9)

CO-HCFA

1234 (28.7)

174 (33.8)

1060 (28.0)

CA

2457 (57.1)

258 (50.1)

2199 (58.1)

837 (19.5)

101 (19.6)

736 (19.4)

0.927

1397 (32.5)

182 (35.3)

1215 (32.1)

0.140

32 (0.7)

7 (1.4)

25 (0.7)

0.083

DM

1024 (23.8)

127 (24.7)

897 (23.7)

0.629

COPD

790 (18.4)

88 (17.1)

702 (18.5)

0.424

CLD

229 (5.3)

27 (5.2)

202 (5.3)

0.930

CVA

320 (7.4)

48 (9.3)

272 (7.2)

0.083

Cognitive impairment/Dementia

337 (7.8)

49 (9.5)

288 (7.6)

0.131

544 (12.7)

67 (13.0)

477 (12.6)

0.793

MI

261 (6.1)

39 (7.6)

222 (5.9)

0.128

PVD

213 (5.0)

33 (6.4)

180 (4.8)

0.105

Connective tissue disease

184 (4.3)

21 (4.1)

163 (4.3)

0.811

809 (18.8)

88 (17.1)

721 (19.0)

0.286

71 (1.7)

8 (1.6)

63 (1.7)

0.853

903 (21.0)

144 (28.0)

759 (20.1)

<0.001

Medical History (%)
Previous CDI
Immunocompromised
HIV (without AIDS)

Heart Failure

GI disease
PUD
Malignancy

Pregnant

9 (0.2)

1 (0.2)

8 (0.2)

0.389

149 (3.5)

20 (3.9)

129 (3.4)

0.579

1487 (39.9)

190 (41.0)

1297 (39.7)

0.586

598 (16.1)

85 (18.5)

513 (15.8)

0.142

2931 (68.2)

375 (72.8)

2556 (67.5)

0.015

1033 (24.0)

115 (22.3)

918 (24.3)

0.339

54 (1.3)

10 (1.9)

44 (1.2)

0.136

653 (15.2)

89 (17.3)

564 (14.9)

0.157

70 (1.6)

9(1.8)

61 (1.6)

0.819

427 (9.9)

52 (10.1)

375 (9.9)

0.891

1274 (29.6)

179 (34.8)

1095 (28.9)

0.007

Fluoroquinolones

660 (15.4)

78 (15.2)

582 (15.4)

0.893

TMP/TMP-SMZ

217 (5.1)

30 (5.8)

187 (4.9)

0.389

Tetracyclines

191 (4.4)

32 (6.2)

159 (4.2)

0.037

614 (14.3)

88 (17.1)

526 (13.9)

0.052

Nitrofuran

99 (2.3)

21 (4.1)

78 (2.1)

0.004

Rifamycin

26 (0.6)

3 (0.6)

23 (0.6)

0.238

1707 (39.7)

190 (36.9)

1517 (40.1)

0.167

811 (18.9)

101 (19.6)

710 (18.8)

0.640

334 (7.8)

49 (9.5)

285 (7.5)

0.114

2194 (51.1)

264 (51.4)

1930 (51.0)

0.879

Morbid Obesity
Medication History (%)
PPI
H2 Receptor Blockers
Antibiotics
Penicillins
Carbapenems
Glycopeptides
Aminoglycosides
Macrolides
Cephalosporins

Nitroimidazole

Immunotherapeutic agents
Steroids
Chemotherapy
Clinical Exposures (%)
Admitted

CDI as reason for admission

1098 (50.1)

143 (54.4)

955 (49.5)

0.141

1579 (37.7)

216 (43.5)

1363 (36.9)

0.005

Dialysis

191 (4.6)

29 (5.8)

162 (4.4)

0.156

Surgery

561 (13.4)

77 (15.5)

484 (13.1)

0.140

1890 (43.9)

218 (42.3)

1672 (44.2)

0.713

Emergency room visit

Treatment received
Antibiotics

0.003

Vancomycin
Metronidazole
Fidaxomicin
Others
Stool transplant
Probiotics
More

than

one

treatment

1344 (72.3)

162 (76.1)

1182 (71.9)

479 (25.8)

47 (22.1)

432 (26.3)

28 (1.5)

3 (1.4)

25 (1.5)

7 (0.4)

1 (0.5)

6 (0.4)

9 (0.5)

1 (0.5)

8 (0.5)

0.390

383 (20.3)

40 (18.4)

343 (20.5)

0.454

458 (24.7)

55 (25.8)

403 (24.5)

0.673

163 (3.8)

1 (0.2)

162 (4.3)

<0.001

course duration
Mortality

CO-HCFA=community-onset healthcare facility associated, HCFO=healthcare facility onset,
CA=community-associated, CDI =Clostridiodes difficile infection, HIV=human
immunodeficiency virus, AIDS=acquired immunodeficiency syndrome, DM= diabetes mellitus,
COPD=chronic obstructive pulmonary disease, CLD=chronic liver disease,
CVA=cerebrovascular accident, MI=myocardial infarction, PVD=peripheral vascular disease,
GI=gastrointestinal, PUD=peptic ulcer disease, PPI= Proton pump inhibitors, H2=histamine 2,
TMP=trimethoprim, SMZ=sulfamethoxazole

Table 2. Socio-demographic and Clinical Characteristics of Participants with Recurrent
CDI Stratified by Epidemiological Class
Variable

Total (N,
%)

Epidemiological Class

p-

HCFO

CO-HCFA

CA

(N=83)

(N=174)

(N=258)

value

Socio-demographic characteristics (%)
Year

<0.001

2015

115 (22.3)

17 (20.5)

36 (20.7)

62 (24.0)

2016

86 (16.7)

6 (7.2)

31 (17.8)

49 (19.0)

2017

68 (13.2)

9 (10.8)

22 (12.6)

37 (14.3)

2018

77 (15.0)

10 (12.1)

31 (17.8)

36 (14.0)

2019

68 (13.2)

5 (6.0)

29 (16.7)

34 (13.2)

2020

101 (19.6)

36 (43.4)

25 (14.4)

40 (15.5)

70.0 (23.0)

74.0 (20.0)

71.0 (23.0)

68.0 (26.0)

Age (Median, IQR)
Sex

0.083

Male

175 (34.0)

36 (43.4)

61 (35.1)

78 (30.2)

Female

340 (66.0)

47 (56.6)

113 (64.9)

180 (69.8)

Race

<0.001

White

419 (81.4)

70 (84.3)

134 (77.0)

215 (83.3)

Black

34 (6.6)

5 (6.0)

13 (7.5)

16 (6.2)

1 (0.2)

0 (0.0)

1 (0.6)

0 (0.0)

Asian/American
Indian/Pacific Islander

0.002

Mixed race/Unknown race

61 (11.8)

8 (9.6)

26 (14.9)

27 (10.5)

Ethnicity
Hispanic

0.007
31 (6.5)

2 (2.5)

14 (8.7)

15 (6.3)

448 (93.5)

77 (97.5)

147 (91.3)

224 (93.7)

Previous CDI

101 (19.6)

19 (22.9)

29 (16.7)

53 (20.5)

Immunocompromised

182 (35.3)

47 (56.6)

71 (40.1)

64 (24.8) <0.001

7 (1.4)

3 (3.6)

2 (1.2)

DM

127 (24.7)

36 (43.4)

47 (27.0)

44 (17.1) <0.001

COPD

88 (17.1)

23 (27.7)

32 (18.4)

33 (12.8)

0.006

CLD

27 (5.2)

7 (8.4)

10 (5.8)

10 (3.9)

0.252

CVA

48 (9.3)

13 (15.7)

19 (10.9)

16 (6.2)

0.024

Cognitive

49 (9.5)

17 (20.5)

19 (10.9)

13 (5.0) <0.001

67 (13.0)

23 (27.7)

35 (20.1)

9 (3.5) <0.001

MI

39 (7.6)

11 (13.3)

15 (8.6)

13 (5.0)

0.039

PVD

33 (6.4)

11 (13.3)

14 (8.1)

8 (3.1)

0.003

Connective Tissue Disease

21 (4.1)

6 (7.2)

5 (2.9)

10 (3.9)

0.012

88 (17.1)

9 (10.8)

36 (20.7)

43 (16.7)

0.142

8 (1.6)

3 (3.6)

2 (1.2)

3 (1.2)

0.034

144 (28.0)

22 (26.5)

67 (38.5)

55 (21.3) <0.001

20 (3.9)

10 (12.1)

6 (3.5)

4 (1.6) <0.001

Non-Hispanic
Medical History (%)

HIV (without AIDS)

2 (0.8)

0.435

0.025

Impairment/Dementia
Heart Failure

GI disease
PUD
Malignancy
Morbid Obesity
Medication History (%)

PPI

190 (41.0)

47 (58.0)

74 (45.4)

69 (31.5) <0.001

85 (18.5)

19 (23.5)

37 (22.7)

29 (13.4)

375 (72.8)

73 (88.0)

145 (83.3)

157 (60.9) <0.001

115 (22.3)

28 (33.7)

61 (35.1)

26 (10.1) <0.001

Carbapenems

10 (1.9)

7 (8.4)

3 (1.7)

0 (0.0) <0.001

Glycopeptides

89 (17.3)

36 (43.4)

45 (25.9)

8 (3.1) <0.001

9 (1.8)

4 (4.8)

4 (2.3)

1 (0.4)

0.003

52 (10.1)

6 (7.2)

12 (6.9)

34 (13.2)

0.067

179 (34.8)

56 (67.5)

87 (50.0)

36 (14.0) <0.001

Fluoroquinolones

78 (15.2)

18 (21.7)

32 (18.4)

28 (10.9)

0.019

TMP/TMP-SMZ

30 (5.8)

6 (7.2)

9 (5.2)

15 (5.8)

0.805

Tetracyclines

32 (6.2)

7 (8.4)

17 (9.8)

8 (3.1)

0.013

88 (17.1)

19 (22.9)

45 (25.9)

Nitrofuran

21 (4.1)

1 (1.2)

10 (5.8)

10 (3.9)

0.012

Rifamycin

3 (0.6)

1 (1.2)

0 (0.0)

2 (0.8)

0.122

190 (36.9)

35 (42.2)

68 (39.1)

87 (33.7)

0.292

101 (19.6)

29 (34.9)

43 (24.7)

29 (11.2) <0.001

49 (9.5)

5 (6.0)

26 (14.9)

18 (7.0) <0.001

264 (51.4)

57 (68.7)

113 (65.3)

94 (36.4) <0.001

143 (54.4)

18 (31.6)

69 (61.6)

56 (59.6) <0.001

216 (43.5)

45 (54.9)

102 (59.0)

69 (28.5) <0.001

H2 Receptor Blockers
Antibiotics
Penicillins

Aminoglycosides
Macrolides
Cephalosporins

Nitroimidazole

Immunochemotherapy
Steroids
Chemotherapy

0.031

24 (9.3) <0.001

Clinical Exposures (%)
Admitted
CDI

as

reason

for

admission
Emergency room visit

Dialysis

29 (5.8)

9 (11.0)

14 (8.1)

Surgery

77 (15.5)

22 (26.8)

45 (26.0)

218 (42.3)

45 (54.2)

77 (44.3)

Treatment received

6 (2.5)

10 (4.2) <0.001
96 (37.2)

Antibiotics
Vancomycin

0.005

0.083
<0.001

162 (76.1)

37 (84.1)

61 (79.2)

64 (69.6)

47 (22.1)

7 (15.9)

13 (16.9)

27 (29.4)

Fidaxomicin

3 (1.4)

0 (0.0)

2 (2.6)

1 (1.1)

Others

1 (0.5)

0 (0.0)

1 (1.3)

0 (0.0)

1 (0.5)

0 (0.0)

0 (0.0)

1 (1.0)

0.440

Probiotics

40 (18.4)

8 (17.8)

10 (13.0)

22 (22.9)

0.244

More than one treatment

55 (25.8)

15 (34.1)

21 (27.3)

19 (20.7)

0.230

Metronidazole

Stool transplant

course
CO-HCFA=community-onset healthcare facility associated, HCFO=healthcare facility onset,
CA=community-associated, CDI =Clostridiodes difficile infection, HIV=human
immunodeficiency virus, AIDS=acquired immunodeficiency syndrome, DM= diabetes mellitus,
COPD=chronic obstructive pulmonary disease, CLD=chronic liver disease,
CVA=cerebrovascular accident, MI=myocardial infarction, PVD=peripheral vascular disease,
GI=gastrointestinal, PUD=peptic ulcer disease, PPI= Proton pump inhibitors, H2=histamine 2,
TMP=trimethoprim, SMZ=sulfamethoxazole

Table 3. Factors Associated with Recurrent CDI
Variable

Model 1#

Model 2##

Model 3###

Odds Ratio

Odds Ratio

Odds Ratio

(95% Confidence

(95% Confidence

(95% Confidence

Interval)

Interval)

Interval)

Socio-demographics
2016

0.73 (0.54, 1.00) *

0.68 (0.44, 1.05)

0.68 (0.44, 1.06)

2017

0.59 (0.42, 0.83) *

0.43 (0.26, 0.72) *

0.43 (0.26, 0.73) *

2018

0.69 (0.50, 0.96) *

0.59 (0.37, 0.95) *

0.60 (0.37, 0.97) *

2019

0.69 (0.49, 0.97) *

0.50 (0.30, 0.84) *

0.50 (0.30, 0.84) *

2020

0.98 (0.72, 1.32)

0.72 (0.46, 1.12)

0.73 (0.46, 1.16)

Age

1.02 (1.01, 1.02) *

1.01 (1.00, 1.02)

1.01 (1.00, 1.02)

Female Sex

1.20 (0.98, 1.46)

1.22 (0.92, 1.63)

1.22 (0.92, 1.63)

Black

0.61(0.42, 0.89) *

0.50 (0.31, 0.83) *

0.50 (0.30, 0.83) *

Asian/American Indian/Pacific

0.27 (0.04, 1.98)

<0.01 (<0.01, >999.99)

<0.01 (<0.01, >999.99)

Mixed/Unknown race

0.97 (0.54, 1.75)

1.36 (0.58, 3.20)

1.36 (0.58, 3.19)

Hispanic

0.90 (0.51, 1.58)

0.64 (0.28, 1.50)

0.65 (0.28, 1.51)

PPI

0.85 (0.64, 1.13)

0.85 (0.64, 1.13)

H2 Receptor Blocker

0.98 (0.68, 1.41)

0.97 (0.67, 1.39)

Antibiotics

1.21 (0.80, 1.81)

1.21 (0.81, 1.81)

Islander

Medication History

Penicillin

1.03 (0.74, 1.44)

1.02 (0.73, 1.42)

Cephalosporins

1.13 (0.81, 1.57)

1.10 (0.79, 1.54)

Tetracyclines

1.05 (0.60, 1.85)

1.05 (0.60, 1.85)

Nitroimidazoles

0.93 (0.64, 1.35)

0.93 (0.65, 1.34)

Nitrofurans

2.38 (1.23, 4.59) *

2.37 (1.23, 4.58) *

0.86 (0.62, 1.18)

0.85 (0.62, 1.17)

Previous CDI

1.03 (0.74, 1.44)

1.03 (0.74, 1.44)

Immunocompromised

1.20 (0.89, 1.61)

1.19 (0.88, 1.60)

CVA

0.91 (0.58, 1.43)

0.90 (0.57, 1.41)

Cognitive

0.91 (0.58, 1.42)

0.91 (0.58, 1.42)

1.52 (1.11, 2.08) *

1.51 (1.11, 2.07) *

CDI as reason for admission

1.48 (1.10, 2.01) *

1.46 (1.07, 12.01) *

Emergency Room

1.32 (1.00, 1.76)

1.28 (0.95, 1.71)

Dialysis

1.45 (0.85, 2.47)

1.44 (0.85, 2.46)

Surgery

1.14 (0.80, 1.64)

1.11 (0.77, 1.59)

Immunotherapy
Clinical History

Impairment/Dementia
Malignancy
Clinical Exposures

Epidemiological Class
CO-HCFA

1.10 (0.74, 1.63)

CA

0.93 (0.61, 1.42)
* Statistically significant

PPI= Proton pump inhibitors, H2=histamine 2, CDI =Clostridiodes difficile infection,
CVA=cerebrovascular accident, CO-HCFA=community-onset healthcare facility associated,
CA=community-associated
#Model

1 contains year of incident CDI diagnosis, age, sex, race, and ethnicity. ##Model 2

contains, in addition to model 1 variables, use of PPI, H2 receptor blocker, antibiotics, penicillin,
cephalosporin, tetracycline, nitroimidazole, nitroimidazoles, nitrofurans, immunotherapy,
previous CDI, immunocompromised states, CVA, cognitive impairment/dementia, malignancy,
admission due to CDI, emergency room use, dialysis, and surgery. ###Model 3 contains, in
addition to variables in model 2, the epidemiological class of cases.

APPENDIX III – Supplemental material
Table S1a. Comparison of Sociodemographic Characteristics of Observations Selected for
Analysis with Excluded Observations.
Variable (%)

Total (N, %)

Selected for Analysis

Not Selected for Analysis

(N=4301)

(N=2722)

Year

<0.001

2015

1429 (20.4)

751 (17.5)

678 (24.9)

2016

1259 (17.9)

744 (17.3)

515 (18.9)

2017

1148 (16.4)

685 (15.9)

463 (17.0)

2018

1256 (17.9)

789 (18.3)

467 (17.2)

2019

999 (14.2)

632 (14.7)

367 (13.5)

2020

932 (13.3)

700 (16.3)

232 (8.5)

68.0 (25.0)

65.0 (26.0)

73.0 (23.0)

Age (Median. IQR)
Sex

2858 (40.7)

1640 (38.1)

1218 (44.8)

Female

4165 (59.3)

2661 (61.9)

1504 (55.3)

Race

<0.001

White

4958 (70.6)

3169 (73.68)

1789 (65.7)

Black

751 (10.7)

430 (10.0)

321 (11.8)

50 (0.7)

38 (0.9)

12 (0.4)

1264 (18.0)

664 (15.4)

600 (22.0)

Indian/Pacific Islanders
Mixed/Unknown race

<0.001
<0.001

Male

Asian/American

p-value

Ethnicity

0.010

Hispanic
Non-Hispanic

476 (7.8)

327 (8.4)

149 (6.6)

5662 (92.3)

3556 (91.6)

2106 (93.4)

401 (6.1)

163 (3.8)

238 (10.5)

Mortality
Epidemiological Class

<0.001
<0.001

HCFO

2852 (41.3)

610 (14.2)

2242 (86.2)

CO-HCFA

1264 (18.3)

1234 (28.7)

30 (1.2)

CA

2708 (39.2)

2457 (57.1)

251 (9.7)

HCFO=healthcare facility onset, CO-HCFA=community-onset healthcare facility associated,
CA=community-associated

Table S1b. Comparison of Sociodemographic Characteristics of Incident HCFO Cases
Selected for Analysis with Excluded Incident HCFO cases.
Variable (%)

Total (N, %)

HCFO Cases

HCFO Cases Not

Selected for Analysis

Selected for Analysis

(N=610)

(N=2242)

Year

<0.001

2015

657 (23.0)

82 (13.4)

575 (25.7)

2016

527 (18.5)

79 (13.0)

448 (20.0)

2017

451 (15.8)

74 (12.1)

377 (16.8)

2018

507 (17.8)

100 (16.4)

407 (18.2)

2019

378 (13.3)

55 (9.0)

323 (14.4)

2020

332 (11.6)

220 (36.1)

112 (5.0)

74.0 (22.0)

73.0 (22.0)

75.0 (22.0)

Age (Median. IQR)
Sex

1288 (45.2)

289 (47.4)

999 (44.6)

Female

1564 (54.8)

321 (52.6)

1243 (55.4)

Race

<0.001

White

1962 (68.8)

470 (77.1)

1492 (66.6)

Black

367 (12.9)

78 (12.8)

289 (12.9)

13 (0.5)

3 (0.5)

10 (0.5)

510 (17.9)

59 (9.7)

451 (20.1)

Indian/Pacific Islanders
Mixed/Unknown race

0.009
0.215

Male

Asian/American

p-value

Ethnicity
Hispanic
Non-Hispanic
Mortality

0.283
159 (6.4)

43 (7.4)

116 (6.1)

2317 (93.6)

540 (92.6)

1777 (93.9)

309 (12.0)

72 (11.8)

237 (12.0)

HCFO = Healthcare facility onset

0.877

Table S2. Classification of Selected Antibiotics
Class Name

Antibiotic Variables

Penicillins

Amoxicillin, Amoxicillin/Clavulanic Acid, Ampicillin, Ampicillin/Sulbactam, Penicillin,
Piperacillin-Tazobactam

Aminoglycosides

Amikacin, Gentamicin, Tobramycin

Macrolides

Azithromycin, Clarithromycin, Clindamycin, Daptomycin

Cephalosporins

Cefazolin, Cefixime, Cefepime, Cefotaxime, Cefoxitin, Cefpodoxime, Ceftaroline,
Ceftazidime, Ceftazidime/avibactam, Ceftizoxime, Ceftolozane/tazobactam, Ceftriaxone,
Cefuroxime, Cephalexin

Fluoroquinolones

Ciprofloxacin, Delafloxacin, Levofloxacin, Moxifloxacin

TMP/TMP-SMZ

Trimethoprim, Trimethoprim-Sulfamethoxazole

Glycopeptides

Dalbavancin, Vancomycin, Oritavancin, Telavancin

Carbapenems

Doripenem, Ertapenem, Imipenem/cilastatin, Meropenem, Meropenem/vaborbactam

Tetracyclines

Doxycycline

Nitroimidazoles

Metronidazole

Nitrofurans

Nitrofurantoin

Rifamycin

Rifaximin

Table S3. Missing Values for Recurrent CDI Stratified by Epidemiological Class
Variable

Total
Missing

Epidemiological Class Missing
HCFO

CO-HCFA

CA

(N, %)
Sociodemographic (%)
Year

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Sex

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Race

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

36 (7.0)

4 (4.8)

13 (7.5)

19 (7.4)

Previous CDI

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Immunocompromised

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

HIV (without AIDS)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

DM

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

COPD

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

CLD

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

CVA

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Cognitive Impairment/Dementia

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Heart Failure

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

MI

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

PVD

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Age (Median, IQR)

Ethnicity
Medical History (%)

Connective Tissue Disease

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

GI disease

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

PUD

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Malignancy

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Morbid Obesity

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

52 (10.1)

2 (2.4)

11 (6.3)

39 (15.1)

55 (10.7))

2 (2.4)

11 (6.3)

42 (16.3)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Penicillins

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Carbapenems

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Glycopeptides

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Aminoglycosides

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Macrolides

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Cephalosporins

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Fluoroquinolones

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

TMP/TMP-SMZ

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Tetracyclines

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Nitroimidazole

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Nitrofuran

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Rifamycin

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Medication History (%)
PPI
H2 Receptor Blockers
Antibiotics

Immunotherapy
Steroids

Chemotherapy

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (0.2)

0 (0.0)

1 (0.6)

0 (0.0)

Emergency room visit

18 (3.5)

1 (1.2)

1 (0.6)

16 (6.2)

Dialysis

15 (2.9)

1 (1.2)

1 (0.6)

13 (5.0)

Surgery

19 (3.7)

1 (1.2)

1 (0.6)

17 (6.6)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Clinical Exposures (%)
Admitted

Treatment Received

CO-HCFA=community-onset healthcare facility associated, HCFO=healthcare facility onset,
CA=community-associated, CDI =Clostridiodes difficile infection, HIV=human
immunodeficiency virus, AIDS=acquired immunodeficiency syndrome, DM= diabetes mellitus,
COPD=chronic obstructive pulmonary disease, CLD=chronic liver disease,
CVA=cerebrovascular accident, MI=myocardial infarction, PVD=peripheral vascular disease,
GI=gastrointestinal, PUD=peptic ulcer disease, PPI= Proton pump inhibitors, H2=histamine 2,
TMP=trimethoprim, SMZ=sulfamethoxazole

Table S4. Univariate Regression Showing Factors Associated with Recurrent CDI
Variable

Univariate Analysis
Odds Ratio

p-value

(95% Confidence
Interval)
Socio-demographic Characteristics
2016 (vs 2015)

0.72 (0.54, 0.98)

0.034

2017 (vs 2015)

0.61 (0.44, 0.84)

0.002

2018 (vs 2015)

0.60 (0.44, 0.81)

0.001

2019 (vs 2015)

0.67 (0.48, 0.92)

0.013

2020 (vs 2015)

0.93 (0.70, 1.25)

0.635

Age

1.02 (1.01, 1.02)

<0.001

Female Sex (vs Male Sex)

1.23 (1.01, 1.49)

<0.001

Black (vs White)

0.56 (0.39, 0.81)

0.002

Asian/American Indian/Pacific Islander (Vs White)

0.18 (0.02, 1.30)

0.088

Mixed Race/Unknown Race (vs White)

0.66 (0.50, 0.88)

0.005

Hispanic (vs non-Hispanic)

0.73 (0.50, 1.07)

0.103

CO-HCFA (vs HCFO)

1.04 (0.79, 1.38)

0.773

CA (vs HCFO)

0.75 (0.57, 0.97)

0.029

Previous CDI

1.01 (0.80, 1.28)

0.926

Immunocompromised

1.16 (0.95, 1.40)

0.140

Medical History

HIV (without AIDS)

2.07 (0.89, 4.82)

0.090

DM

1.05 (0.85, 1.31)

0.629

COPD

0.91 (0.71, 1.16)

0.424

CLD

0.98 (0.65, 1.48)

0.930

CVA

1.33 (0.96, 1.83)

0.084

Cognitive Impairment/Dementia

1.28 (0.93, 1.76)

0.131

Heart Failure

1.04 (0.79, 1.37)

0.790

MI

1.32 (0.92, 1.87)

0.128

PVD

1.37 (0.94, 2.01)

0.106

Connective Tissue Disease

0.95 (0.59, 1.50)

0.811

GI disease

0.88 (0.69, 1.12)

0.287

PUD

0.93 (0.44, 1.96)

0.853

Malignancy

1.55 (1.26, 1.91)

<0.001

Morbid Obesity

1.15 (0.71, 1.85)

0.580

PPI

1.06 (0.87, 1.29)

0.586

H2 Receptor Blockers

1.21 (0.94, 1.56)

0.143

Antibiotics

1.29 (1.05, 1.58)

0.016

Penicillins

0.90 (0.72, 1.12)

0.340

Carbapenems

1.68 (0.84, 3.37)

0.140

Glycopeptides

1.19 (0.93, 1.53)

0.158

Aminoglycosides

1.09 (0.54, 2.20)

0.819

Macrolides

1.02 (0.75, 1.39)

0.891

Medication History

Cephalosporins

1.31 (1.08, 1.59)

0.007

Fluoroquinolones

0.98 (0.76, 1.27)

0.894

TMP/TMP-SMZ

1.19 (0.80, 1.77)

0.389

Tetracyclines

1.51 (1.02, 2.24)

0.039

Nitroimidazole

1.28 (1.00, 1.64)

0.052

Nitrofuran

2.02 (1.24, 3.30)

0.005

Rifamycin

0.96 (0.29, 3.21)

0.946

0.87 (0.72, 1.06)

0.167

Steroids

1.06 (0.84, 1.33)

0.640

Chemotherapy

1.29 (0.94, 1.78)

0.115

1.01 (0.84, 1.22)

0.879

1.21 (0.94, 1.57)

0.141

Emergency room visit

1.32 (1.09, 1.59)

0.005

Dialysis

1.34 (0.89, 2.02)

0.157

Surgery

1.22 (0.94, 1.58)

0.141

Treatment Received

1.00 (0.51, 1.97)

0.991

Metronidazole (vs Vancomycin)

0.79 (0.56, 1.12)

0.187

Fidaxomicin (vs Vancomycin)

0.88 (0.26, 2.93)

0.829

Others (vs Vancomycin)

1.22 (0.15, 10.17)

0.857

Stool transplant

0.96 (0.12, 7.70)

0.969

Probiotics

0.87 (0.61, 1.25)

0.455

More than one treatment course (vs one course)

1.07 (0.77, 1.49)

0.673

Immunotherapy

Clinical Exposures
Admitted
CDI as reason for admission

Mortality

0.04 (0.01, 0.31)

0.002

CO-HCFA=community-onset healthcare facility associated, HCFO=healthcare facility onset,
CA=community-associated, CDI =Clostridiodes difficile infection, HIV=human
immunodeficiency virus, AIDS=acquired immunodeficiency syndrome, DM= diabetes mellitus,
COPD=chronic obstructive pulmonary disease, CLD=chronic liver disease,
CVA=cerebrovascular accident, MI=myocardial infarction, PVD=peripheral vascular disease,
GI=gastrointestinal, PUD=peptic ulcer disease, PPI= Proton pump inhibitors, H2=histamine 2,
TMP=trimethoprim, SMZ=sulfamethoxazole

APPENDIX IV – Case Report Forms
CRF used in 2015 to 2018

CRF used from 2019-2020

